MOTS-c, explained
A 16-amino-acid peptide encoded in mitochondrial DNA and first described in 2015. What the early metabolism research has looked at, and why most human data so far are observational.
MOTS-c is a small peptide with an unusual origin: its instructions are carried not in the cell's main genome but in the separate DNA of the mitochondria. First described by researchers in 2015, it is among the newest peptides to attract attention, and its human research is correspondingly young. This guide explains what MOTS-c is, what has been studied, and where the evidence stops.
What MOTS-c is
Mitochondria — the structures that produce most of a cell's usable energy — carry their own small genome. For a long time that genome was thought to code for only a short, fixed list of proteins. MOTS-c is one of a handful of “mitochondrial-derived peptides” identified since: a chain of 16 amino acids encoded within a mitochondrial gene previously known only for making part of the cell's protein-building machinery.
The body makes MOTS-c on its own, and it can be measured in blood and in muscle. The MOTS-c used in research and in compounding is a synthetic copy of that sequence.
What researchers have studied
In laboratory and animal studies, MOTS-c has been examined in the context of metabolism: how cells take up and use glucose, how they respond to insulin, and how they adapt to exercise and other physical stress. A recurring observation in that work is activation of AMPK, an enzyme that acts as a cellular energy sensor.
In people, most of the published work is observational. It measures the body's own MOTS-c levels in different groups — before and after exercise, for example, or across age ranges — rather than testing MOTS-c given as a treatment. Observational findings can suggest questions worth studying; they cannot show what happens when the peptide is administered.
Where the evidence stops
Studies in which MOTS-c is given to humans are scarce, and there are no large, controlled clinical trials establishing that it is safe or effective for any condition. Findings in mice describe what a molecule can do in an experimental system; they do not show what it will do in a person. Long-term safety has not been characterized.
What a prescribed protocol looks like
The form, the amount, the schedule and the duration of any protocol are decisions made by the prescribing provider for the individual patient. Nothing in this article should be read as a dosing recommendation. If a source online offers you MOTS-c without a licensed provider and a real evaluation involved, treat that as a warning sign, not a shortcut.
FDA status and compounding: what to know
The regulatory picture here deserves precision. MOTS-c is not an FDA-approved medication: no product containing it has been approved by the FDA for any use. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety or efficacy.
In July 2026, an FDA advisory committee reviewed whether MOTS-c should be added to the list of substances that pharmacies may use in compounding. That review concerns what licensed pharmacies may prepare on a valid prescription. It is not an FDA approval, and it does not establish that MOTS-c is safe or effective for any use.
MOTS-c is not yet available through Peptivik. If and when it is offered, it will be by prescription only, after an evaluation by a licensed provider, and prepared for individual patients by state-licensed US compounding pharmacies — a different regulatory lane than FDA premarket review, and one you should expect any honest platform to disclose plainly.
If you compete in a tested sport
Anti-doping rules restrict a number of peptides and metabolic agents. If you are subject to drug testing, check your sport's current prohibited list before considering MOTS-c.
Questions worth asking a provider
- What the human evidence does and does not show for the reason you are considering it.
- What is known, and what is not known, about side effects and long-term safety.
- How it would fit alongside your current medications and health conditions.
- What they would want to evaluate first, and what would lead them to advise against it.
The bottom line
MOTS-c is a 16-amino-acid peptide encoded in mitochondrial DNA and studied for its role in how cells manage energy. The laboratory and animal research is active; trials in people are scarce. It is not FDA-approved for any use. Whether it is appropriate for you is a decision that belongs with a licensed provider who can weigh that limited evidence against your health history.
This content is educational and not a substitute for advice from your provider.